RE: Patient INVESTOR wins!!17 Feb 2026 10:48
This is what I said on 10/2/26:
EME – valuation, prospects & what matters next10 Feb 2026 11:41
At a £4–5m mcap we clearly arent being valued on reserves, NPVs or future gas cashflow. At the moment EMEs basically being priced on 'survival' plus a bit of optional exposure to Mako, nothing more. That's crazy.
The January RNS did change things though. No more direct cash calls, economic interest kept via the SPV, funded route to development and first gas pencilled in for 2027. That takes the existential risk off the table, but it still doesn’t give the market enough to hang a proper valuation on (yet). That will come.
The big difference vs Conrad isn’t about the asset it’s about clarity. Conrad has control, funding and a defined economic picture. EME doesn’t, at least not publicly, and that’s why the future cashflow isnt being priced in yet.
What’s not priced in yet:
– what the SPV looks like
– who the farminee actually is
- Indonesian approvals / FID
– how the balance sheet and debt is being restructured
– what EME’s cashflow priority really is / future projects etc
Until that’s nailed down, the market are giving lots a nice, low point of entry v potential here.
A rerate will come once we have the final SPV docs, clarity on the economics, a credible operator named, debt resolved etc as above.
High risk, yes -but high reward to those prepared to ride the diops and wait it out.
GLA